Efficacy and Safety of Intravenous Secukinumab in Patients With Active Axial Spondyloarthritis: Results From a Randomized, Placebo‐Controlled, Phase 3 Study
IV secukinumab was effective for the treatment of adults with active axSpA over 52 weeks. The safety profile was consistent with that in previous reports on subcutaneous secukinumab.
Authors
- Eva Dokoupilová
- Atul Deodhar (ORCID: https://orcid.org/0000-0002-2130-1246)
- Karen Kapur (ORCID: https://orcid.org/0000-0003-3222-7683)
- Guillermo J. Valenzuela (ORCID: https://orcid.org/0000-0003-1552-8812)
- Alan Kivitz (ORCID: https://orcid.org/0000-0002-1045-1310)
- Susanne Rohrer
- Karel Pavelká (ORCID: https://orcid.org/0000-0003-1952-8422)
- Hanno B. Richards
- Jerzy Supronik
Institutions
- Novartis (Switzerland) (CH)
- Oregon Health & Science University (US)
- Charles University (CZ)
- Altoona Center for Clinical Research (US)
- Medical Plus (CZ)
- NZOZ Centrum Alergologii (PL)
- Dermatology Specialists (US)
Publication Details
- Journal
- Arthritis & Rheumatology
- Published
- 2024-09-19
- DOI
- https://doi.org/10.1002/art.42993
- Citations
- 4
- Primary Topic
- Spondyloarthritis Studies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.88
Funders
- Novartis Pharmaceuticals Corporation